1 / 17

Roger L. Bertholf, Ph.D. Associate Professor of Pathology

Susceptibility of immunoassays to interference from human anti-animal antibodies: How common a problem ?. Roger L. Bertholf, Ph.D. Associate Professor of Pathology University of Florida Health Science Center/Jax. Human anti-animal antibodies. First described in 1971 by Ammann and Hong

yul
Download Presentation

Roger L. Bertholf, Ph.D. Associate Professor of Pathology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Susceptibility of immunoassays to interference from human anti-animal antibodies: How common a problem? Roger L. Bertholf, Ph.D. Associate Professor of Pathology University of Florida Health Science Center/Jax

  2. Human anti-animal antibodies • First described in 1971 by Ammann and Hong • Potential to cause positive or negative interferences • Anti-isotype or anti-idiotype • Anti-mouse antibodies are most common • Incidence is not certain

  3. Substrate E E E E E E 2nd antibody Specimen S P Two-site “sandwich” enzyme immunoassay

  4. Substrate E E E E E 2nd antibody S P HAMA “bridging” interference

  5. E E E E HAMA blocking interference

  6. Labeled antigen Specimen Wash Competitive immunoassay

  7. HAMA blocking interference

  8. Case Report The laboratory director was consulted by a gynecologist about discrepant CA-125 results on a patient being monitored for recurrence of a surgically removed ovarian tumor. CA-125 results from a referral laboratory had been consistently high and increasing, while results from the hospital laboratory were within normal limits.

  9. CA-125 • A large glycoprotein expressed by tissues originating from the müllerian ducts • Mab OC 125 was isolated by Bast and colleagues in 1981, using cells from a serous papillary cystadenocarcinoma • Useful for detecting and monitoring ovarian tumors • Also elevated in endometrial, pancreatic, breast, colorectal, lung and GI carcinomas

  10. Clinical utility of CA-125 • Lacks sensitivity and specificity as a screening test for ovarian cancer • Normal in 50% of stage I ovarian cancers • PV+ 5% • Very sensitive indicator of recurrence following surgical resection • Failure to return to normal after chemotherapy is indicative of drug-resistant disease

  11. Referral Lab SHJ

  12. AbbottRoche

  13. Follow-up studies • HAMA quantitation (IRMA)* • Result = 196 ng/mL (0 – 188) • CA-125 with heterophilic blocking reagent* • Without blocking reagent: 211.5 U/mL • With blocking reagent: 11.0 U/mL *Scantibodies, Inc., Santee, CA

  14. Sources of foreign IgG exposure • Imaging reagents • Pharmaceuticals • Vaccines • Abzymes (proposed)

  15. Incidence of HAMA • Clinical trials • 0-100% reported • Population studies • 72 of 10,000 blood donors (1990 abs.) • 92 of 1,008 blood donors (1986, indir.) • 51 of 67 blood donors (1991) • 8 of 10 infants (1991)

  16. Conclusions • HAMA can cause clinically significant elevations in CA-125 assays • Different immunoassays may not respond equally to the presence of HAMA • The population frequency of HAMA is not known, but is likely to increase • Interference may occur at modest concentrations of HAMA

  17. “Beware of false knowledge; it is more dangerous than ignorance.” - George Bernard Shaw (1856–1950) “Something is better than nothing, unless ‘something’ is wrong, in which case nothing is better than something.” - John Savory

More Related